Present and future therapeutic strategies in non-alcoholic fatty liver disease (Q36936358)

17 August 2017

1 reference

title

Present and future therapeutic strategies in non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

17 August 2017

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

Giuseppe Calamita

1

1 reference

PubMed ID

17845148

17 August 2017

Piero Portincasa

series ordinal

2

1 reference

PubMed ID

17845148

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Therapeutic Targets

17 August 2017

1 reference

17 August 2017

11

1 reference

17 August 2017

1231-1249

1 reference

17 August 2017

9

1 reference

Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Prevalence of and risk factors for fatty liver in a general population of Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Retinoid x receptor heterodimers in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Cytokines in alcoholic and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Obesity, Inflammation, and Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Mitochondria in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Role of inflammation in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

21 January 2018

From fat to inflammation

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Influence of body fat distribution on free fatty acid metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Leptin and the regulation of body weight in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Leptin selectively decreases visceral adiposity and enhances insulin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Genomics of liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Performance of serum marker panels for liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The diagnostic value of liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Current pharmacological treatment of nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Dietary composition and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effect of a moderately energy-restricted diet on obese patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Hepatic effects of dietary weight loss in morbidly obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A review of the metabolic effects of sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effect of fatty acids on glucose production and utilization in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Molecular genetic aspects of human mitochondrial disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Systematic review: ursodeoxycholic acid--adverse effects and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Gallstone disease: Symptoms and diagnosis of gallbladder stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Cholesterol gallstone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Pathways of cholesterol crystallization in model bile and native bile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effect of ursodeoxycholic acid on hepatic steatosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Animal models of steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Increased orocecal transit time in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Development of alcoholic fatty liver and fibrosis in rhesus monkeys fed a low n-3 fatty acid diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Non-alcoholic steatohepatitis: from cell biology to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Physiological roles of glycerol-transporting aquaporins: the aquaglyceroporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Aquaporins: a promising target for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Progressive adipocyte hypertrophy in aquaporin-7-deficient mice: adipocyte glycerol permeability as a novel regulator of fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Differential expression of aquaporin 7 in adipose tissue of lean and obese high fat consumers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

PPARalpha governs glycerol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Water handling and aquaporins in bile formation: recent advances and research trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Molecular mechanisms and drug development in aquaporin water channel diseases: aquaporin superfamily (superaquaporins): expansion of aquaporins restricted to multicellular organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Aquaporins as potential drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

More than just water channels: unexpected cellular roles of aquaporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Interleukin (IL)-6 mRNA Expression is Stimulated by Insulin, Isoproterenol, Tumour Necrosis Factor Alpha, Growth Hormone, and IL-6 in 3T3-L1 Adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Caveolin-1 is essential for liver regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Lipid metabolism in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Caveolin-1 and liver regeneration: role in proliferation and lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

A functional variant of the adipocyte glycerol channel aquaporin 7 gene is associated with obesity and related metabolic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Clinical proteomics: revolutionizing disease detection and patient tailoring therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

LXRS and FXR: the yin and yang of cholesterol and fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Nuclear bile acid receptor FXR as pharmacological target: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Polycystic ovary syndrome: syndrome XX?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

The nutritional status modulates preservation-reperfusion injury in rat fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.9.1231

10.1517/14728222.11.9.1231

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17845148